A draft about government action
HHS, short for the Department of Health and Human Services, addressed certain pharmacy-made peptide drugs in a draft published October 30, 2026. The draft says that when its requirements are met, HHS does not plan to act against the pharmacy or doctor for making the drug.
The medicine must be made for a person named on a prescription, by a doctor or pharmacy with a state license.
Under the federal law’s section 503A, a pharmacy or doctor may make medicine for a person named on a prescription if the legal requirements are met.
The prescription alone is not enough; every other requirement in the draft still applies.
The draft covers KPV, epitalon and semax only in the chemical versions and ways of giving the drug listed in Appendix B. The draft also names MOTS-c, BPC-157 and TB-500. It sets limits on the drug forms and how they are given.
The draft covers one peptide ingredient in each drug, rather than a mix of peptides.
Peptide blends are left out, as are 503B outsourcing facilities—businesses registered with FDA to make sterile medicines.
These facilities often make batches for clinics or hospitals and do not need prescriptions naming individual people. Sterile describes the absence of living germs.
What that does not establish
The draft is not binding. It gives no FDA approval.
The 503A bulks list names extra raw drug ingredients that federal law allows for this kind of pharmacy-made medicine.
At the check on November 3, 2026, all six were still missing from the list. Even if HHS takes no action under the draft, the peptide is still not added to that list.
At the July 2026 meeting, FDA’s Pharmacy Compounding Advisory Committee considered whether peptide ingredients belonged on that list. HHS reports that the committee favored adding these six peptides.
HHS published this official account of the vote. In the November 3, 2026 review, FDA’s page for the meeting still had no transcript or minutes, the written meeting record.
A committee vote is advice to FDA. To change the list, FDA still needs a separate process for making a rule, with public comment.
For a Richmond prescription, ask both the pharmacist and your clinician—a nurse practitioner, doctor or physician assistant—about the exact drug they plan to make. Which part of the draft covers that drug, and how would each requirement be met? A policy headline cannot answer the product-specific question for you.
Research wording needs scrutiny
FDA warnings reviewed November 3, 2026 concern research-labeled peptide drugs offered for human use.
FDA used the sellers’ claims to judge intended use. A research label did not change FDA’s finding that the sellers were offering the drugs for people to use.
For Richmond care, ask for a prescription discussion and a verifiable pharmacy rather than treating research wording as reassurance.
